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Summary
Background Reported incidence of B-cell malignancies shows substantial geographical variation, being more common 
in the Americas and Europe than in Africa. This variation might reflect differences in diagnostic capability, inherited 
susceptibility, and infectious exposures. Monoclonal B-cell lymphocytosis (MBL) is a precursor lesion that can be 
screened for in apparently healthy people, allowing comparison of prevalence across different populations 
independently of health-care provision. We aimed to compare the prevalence and phenotypic characteristics of MBL 
in age-and-sex-matched populations from rural Uganda and the UK. 
Methods In this cross-sectional study, we recruited volunteers aged at least 45 years who were seronegative for HIV-1 
from the established Ugandan General Population Cohort and obtained their whole-blood samples. We also obtained 
blood samples from anonymised waste material of age-and-sex-matched individuals (aged >45 years, with a normal 
blood count and no history of cancer) in the UK. We used flow cytometry to determine the presence of MBL, defined 
according to standard diagnostic criteria, in the samples and compared differences in the proportion of cases with 
chronic lymphocytic leukaemia (CLL)-phenotype MBL and CD5-negative MBL, as well as differences in absolute 
monoclonal B-cell count between the two cohorts.
Findings Between Jan 15 and Dec 18, 2012, we obtained samples from 302 Ugandan volunteers and 302 UK individuals 
who were matched by age and sex to the Ugandan population. Overall MBL prevalence was higher in the Ugandan 
participants (42 [14%] individuals) than in the UK cohort (25 [8%]; p=0·038). CLL-phenotype MBL was detected in 
three (1%) Ugandan participants and 21 (7%) UK participants (p=0·00021); all three Ugandan participants had 
absolute monoclonal B-cell count below one cell per µL, whereas the 21 UK participants had a median absolute 
number of circulating neoplastic cells of 4·6 (IQR 2–12) cells per µL. The prevalence of CD5-negative MBL was 
higher in the Ugandan cohort (41 [14%], of whom two [5%] also had CLL-phenotype MBL) than in the UK cohort 
(six [2%], of whom two [33%] also had CLL-phenotype MBL; p<0·0001), but the median absolute B-cell count was 
similar (227 [IQR 152–345] cells per µL in the Ugandan cohort vs 135 [105–177] cells per µL in the UK cohort; p=0·13). 
Interpretation MBL is common in both Uganda and the UK, but the substantial phenotypic differences might reflect 
fundamental differences in the pathogenesis of B-cell lymphoproliferative disorders.
Funding UK Medical Research Council and UK Department for International Development.
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Introduction
B-lymphoproliferative disorders include a wide range of 
both non-malignant and malignant conditions. The 
malignant diseases represent the most frequent adult 
haematological cancers, accounting for more than 50% 
of leukaemia and more than 90% of non-Hodgkin 
lymphoma diagnoses.1 However, major geographical 
variation exists in the reported incidence of B-lympho-
proliferative disorders. According to GLOBOCAN 2012,2 
age-standardised incidence per 100 000 person-years for 
leukaemia and non-Hodgkin lymphoma in the WHO 
African region is 6·4, compared with 18·2 in the WHO 
Americas region and 21·3 in the WHO European region. 
Chronic lymphocytic leukaemia (CLL) is the most 
common adult leukaemia in Europe and the USA but 
incidence seems to be low in Africa, with some data 
suggesting that other B-cell malignancies, such as 
lymphoplasmacytic lymphoma and marginal zone 
lymphomas, might be more frequent than CLL.3 Several 
factors can affect the reported differences in incidence, 
including variable quality of access to cancer care, 
differences in age distribution, and failure to diagnose 
B-lymphoproliferative disorders, especially in the elderly.2 
Monoclonal B-cell lymphocytosis (MBL) is a precursor 
lesion of B-lymphoproliferative disorders and provides a 
useful model for the study of B-cell lymphomagenesis, 
since it can be screened for in otherwise healthy people,4–6 
thereby allowing a comparison of prevalence across 
geographical regions in a way that is independent of 
health-care provision. MBL with a CLL phenotype is 
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common in Europe and the USA and, compared with 
other MBL subtypes, has been relatively well characterised 
in terms of phenotype, genotype, and B-cell receptor 
immunoglobulin gene repertoire.7–13 Furthermore, the 
incidence, rate of disease progression, and inherited 
susceptibility single-nucleotide polymorphism (SNP) 
patterns are well established in US and European 
populations.14–17 MBL of non-CLL phenotype is also 
increasingly recognised, and preliminary data suggest 
that this subtype is less common than CLL-phenotype 
MBL6,18,19 but might be a precursor of entities within the 
spectrum of marginal zone lymphomas, typically of 
splenic type.20,21
Therefore, the study of MBL in Uganda might provide 
insights into the pathogenesis of B-lymphoproliferative 
disorders in sub-Saharan Africa, and comparison with 
data from the UK could deepen these insights. In this 
study, we aimed to assess the prevalence of MBL in a 
rural population in Uganda and compare these findings 
with those from a study of MBL in a UK population.
Methods
Study design and data collection
In this cross-sectional study, we analysed samples from 
participants in rural Uganda and a UK hospital-based 
population (appendix pp 1–2). We recruited volunteers 
aged at least 45 years who were seronegative for HIV-1 
from the Ugandan General Population Cohort, a 
community-based open dynamic cohort with more than 
22 000 people at present. Whole-blood samples were 
obtained from the participants, stored at 4°C overnight, 
and analysed within 24 h. We used a previously reported 
method16 to obtain whole-blood samples from anonymised 
waste material of UK hospital outpatients and primary 
care patients with a normal blood count and no history of 
cancer. These patients were selected to match the age and 
sex distribution of the Ugandan participants.
Ethics approval for sample collection in Uganda was 
provided by the Uganda Virus Research Institute 
Scientific Ethics Committee and the Uganda Council for 
Science and Technology, and for sample collection in the 
UK by the Leeds Teaching Hospitals National Health 
Service Trust Ethics Review Board. In Uganda, study 
personnel read the consent form to all participants, who 
signed or thumb-printed (for those who were illiterate) 
the forms.
Procedures
MBL is a condition in which the B-cell surface 
immunoglobulin light chain κ-to-λ ratio is heavily skewed 
in total B-cells or in a B-cell subset. In previous studies 
the detection of MBL representing a subset of B cells 
(ie, with predominantly polyclonal B cells) has been 
limited to CLL-phenotype cells whereas CD5-negative 
MBL has represented a skewed κ-to-λ ratio in total B 
cells.5,6,18,19 However, in some individuals, immunoglobulin 
light-chain skewing could be detected within B-cell 
subsets defined by CXCR5 (CD185) and LAIR1 (CD305) 
expression. In European populations, these markers are 
strongly expressed in most normal B cells but show 
aberrant expression in most B-lymphoproliferative 
disorders.22 LAIR1 (CD305) expression varies according 
to the type of B-lymphoproliferative disorder: germinal-
centre B-cell malignancies typically have no LAIR1 
expression; Waldenström’s macro globulinaemia usually 
have either no LAIR1 expression or intermediate levels, 
often with both a LAIR1-negative and a LAIR1-positive 
component; and hairy cell leukaemia and splenic 
lymphomas usually have stronger than normal 
expression.22
We used flow cytometry to determine the presence of 
MBL, defined according to the standard diagnostic 
criteria23—κ-to-λ ratio greater than 3:1 or less than 0·3:1, 
or more than 25% of B cells without surface 
immunoglobulin or expressing low levels of surface 
immunoglobulin either in the total B-cell population 
(CD19 positive, CD20 positive), or in one or more pre-
specified B-cell subsets: CD5 positive, CD20 weak, 
Research in context
Evidence before this study
Monoclonal B-cell lymphocytosis (MBL) is a precursor to 
B-cell haematological malignancy that can be used as a model 
for the study of B-cell lymphomagenesis. MBL with a chronic 
lymphocytic leukaemia phenotype is common in Europe and 
the USA and, compared with other MBL subtypes, has been 
relatively well characterised in terms of phenotype, genotype, 
and B-cell receptor immunoglobulin gene repertoire. 
Furthermore, the prevalence, rate of disease progression, and 
inherited susceptibility single-nucleotide polymorphisms 
patterns are well established in the USA and Europe. We 
found no reports of MBL prevalence in Africa on PubMed up 
to Dec 31, 2015 (search term “monoclonal B-cell 
lymphocytosis Africa”).
Added value of this study
To our knowledge, this is the first study to provide data for the 
prevalence and phenotype of MBL in an African country. Overall 
MBL prevalence was slightly higher in rural Uganda than in the 
UK but chronic lymphocytic leukaemia-phenotype MBL was 
infrequent whereas CD5-negative MBL was much more 
common in rural Uganda and showed substantial phenotypic 
differences compared with the UK population. 
Implications of all the available evidence
Although MBL is common in both rural Uganda and the UK, the 
variation in phenotype shows that differences in environmental 
exposure, inherited susceptibility, or both factors affect the type 
of B-cell neoplasms that can develop. 
See Online for appendix
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For the 1000 Genomes project 
see http://browser.1000genomes.
org/index.html
surface immunoglobulin weak (CLL-phenotye); 
CD10 positive; CD305 positive and CD185 negative; 
CD305 positive and CD185 positive; CD305 negative and 
CD185 negative; or CD305 negative and CD185 positive. 
The threshold for positivity was validated against internal 
cellular controls in each case. 
We analysed the immunoglobulin gene repertoire of 
13 Ugandan individuals selected to represent each of the 
MBL categories (three with CLL-type MBL, three with 
CD5-negative MBL, three with a monoclonal B-cell 
subset) and individuals with polyclonal B-cells (four 
individuals). IGHV–IGHD–IGHJ gene rearrangements 
were amplified from genomic DNA (200 ng, extracted 
from at least 2 × 10⁶ peripheral blood mononuclear cells) 
and sequenced according to the standard Roche 454 GS-
Junior sequencing protocol. Productive, in-frame 
sequences were analysed using IMGT HighV-Quest 
software, version 1.3.0.24 Genotype data were generated 
with the Illumina HumanOmni2.5 BeadChip array at the 
Sanger Institute (Cambridge, UK) for 5000 participants 
of the General Population Cohort.25 The data were 
assessed for six SNPs reported to be associated with both 
CLL and MBL, and compared with published UK risk-
allele frequencies.14 Comparisons with African American 
people were made using data from the 1000 Genomes 
project.
Statistical analysis
No formal power calculations were done because of 
insufficient data from Africa, and sample size was 
determined pragmatically. We compared differences in 
the proportion of cases with CLL-phenotype MBL and 
CD5-negative MBL and in absolute monoclonal B-cell 
count between the Ugandan and UK samples. We 
assessed significance using Fisher’s exact test (two-tailed) 
or the Wilcoxon-Mann-Whitney U-test (two-tailed) as 
appropriate, using IBM SPSS version 24.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication. 
Results
Between Jan 15 and Dec 18, 2012, we obtained samples 
from 302 Ugandan volunteers and 302 age-and-sex-
matched UK individuals. 121 (40%) participants from 
Uganda were women aged 40–60 years, 47 (16%) were 
men aged 40–60 years, 90 (30%) were women older than 
60 years, and 44 (15%) were men older than 60 years. The 
UK population was matched exactly by sex and age.
MBL was detected in 42 (14%) of 302 Ugandan 
participants and 25 (8%) of 302 UK participants 
(p=0·038). Monoclonal CLL-phenotype B cells were 
detected in three (1%) Ugandan participants and in 
21 (7%) UK participants (p=0·00021; figure 1). By contrast, 
CD5-negative MBL was more prevalent in the Ugandan 
participants (41 [14%] individuals, of whom two [5%] also 
had CLL-phenotype MBL detectable) than in the UK 
participants (six [2%], of whom two [33%] also had CLL-
phenotype MBL detectable; p<0·0001; figure 1). A mono-
clonal B-cell subset was detectable in 93 (31%) Ugandan 
participants and 21 (7%) UK parti cipants (p<0·0001; 
figure 1). CD10-positive monoclonal B-cell populations 
with a germinal centre phenotype were not detected in 
either population.
In addition to differences in the phenotype of monoclonal 
B cells between the two cohorts, the absolute counts of 
monoclonal B cells also differed significantly (figure 2). All 
three Ugandan participants with CLL-phenotype MBL had 
absolute monoclonal B-cell count below one cell per µL 
and close to the detection limit of the assay. By contrast, in 
the 21 UK participants with CLL-phenotype MBL, the 
median absolute number of circulating neoplastic cells 
was 5 cells per µL (IQR 2–12, range 1–1773). Seven (2%) 
UK participants had more than ten CLL-phenotype 
cells per µL, compared with none in the Ugandan 
participants (p=0·015). Although the prevalence of 
CD5-negative MBL was higher in the Ugandan participants 
than in the UK participants, the median absolute B-cell 
count was similar (227 [IQR 152–345, range 56–947] cells 
Figure 1: Prevalence of MBL in the Ugandan and UK cohorts, by B-cell phenotype 
(A) Proportion of participants with detectable CLL-type MBL and CD5-negative MBL according to the 
2005 diagnostic criteria.22 (B) Proportion of participants with a monoclonal B-cell subset. CLL=chronic lymphocytic 
leukaemia. MBL=monoclonal B-cell lymphocytosis.
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per µL in the Ugandan cohort vs 135 [105–177, 69–503] cells 
per µL in the UK cohort; p=0·13). However, the median 
absolute count of CD5-negative monoclonal B-cell subsets 
was significantly higher in the Ugandan cohort (seven 
[3–15, 1–53] cells per µL) than in the UK cohort (two [2–3, 
1–17] cells per µL; p=0·012).
Differences were also apparent in LAIR1 expression by 
CD5-negative MBL and monoclonal B-cell subsets in the 
two cohorts. Monoclonal B-cell expansions in the UK 
participants typically showed moderate to strong LAIR1 
expression, whereas those in Uganda had weak or 
bimodal expression similar to the IgM-secreting 
lymphoplasmacytic disorder (figure 3). Of 41 CD5-
negative MBL cases in the Ugandan cohort, 40 (98%) had 
LAIR1-negative cells or a combination of both LAIR1-
negative and LAIR1-positive cells, compared with 
two (33%) of six UK cases (p=0·0040). Monoclonal B-cell 
subsets comprised only LAIR1-negative cells or a 
combination of both LAIR1-negative and LAIR1-positive 
cells in 85 (91%) of 93 Ugandan cases, compared with 
four (19%) of 21 UK cases (p<0·0001; figure 3). 
The high prevalence of CD5-negative MBL was 
unexpected; although not initially planned, we extended 
immunophenotyping on 18 samples from rural Uganda 
using a panel of 46 markers with a common backbone of 
CD19, CD20, CD27, CXCR5, and LAIR1 (appendix p 5). 
The samples were from five individuals with CD5-
negative MBL, eight individuals with a monoclonal B-cell 
subset, and five individuals with polyclonal B-cell subsets. 
Although the analysis was not powered to show significant 
differences, some markers—including CD38, CD73, 
CD200, and CD307d (FcRL4)—had at least a five times 
difference in expression by CD5-negative MBL B cells 
compared with polyclonal B cells and at least a two times 
difference in expression by CD5-negative MBL cells 
compared with B cells from cases with a monoclonal 
B-cell subset (appendix p 9). This finding suggests that 
neoplastic expansions might be phenotypically dis-
criminated in a similar manner to the detection of CLL-
phenotype MBL populations.
Immunoglobulin gene repertoire analysis was done in 
13 Ugandan individuals, with a median of 224 (range 39–
2674, IQR 127-428) productive, in-frame IGHV–IGHD–
IGHJ gene rearrangements sequenced per individual. 
Four of these individuals had no detectable MBL clones by 
flow cytometry and, concordantly, next-generation 
sequencing did not detect any significant clonal expansion. 
Three of these individuals were found to carry CD5-
negative MBL by flow cytometry, and we detected a clonal 
population in each one using next-generation sequencing. 
Three individuals had light-chain restriction detectable by 
flow cytometry in a subset of B cells, and clonal expansion 
was identified in one of these individuals (appendix p 6).
In the three individuals with a suspected CLL-phenotype 
population present at the detection limit of the flow 
cytometry assay, next-generation sequencing showed no 
evidence of significant clonal expansion, with the most 
expanded clonotypes representing a 1·3%, 3·1%, and 
3·9% of the B-cell receptor immunoglobulin repertoire, 
respectively in the three individuals. In a post-hoc analysis, 
sequences were cross-compared with a database of 
19 464 CLL sequences including 668 stereotyped CLL 
subsets. In one of the three individuals with a suspected 
CLL-phenotype population, a single, non-expanded 
clonotype was found (IGHV1-2/IGHD3-3/IGHJ6, 
CysAlaLysGlyAlaGlnTyrTyrAspPheTrpSerGlyTyrLeu 
ProTyrTyrTyrGlyMetAspValTrp) clustering to a minor CLL 
subset. In another individual with a monoclonal B-cell 
subset, an expanded clonotype consisting of four identical 
sequences was found (IGHV3-30/IGHD2-21/IGHJ4, 
CysValLysAspAspGlnTrpGlyProAspTyrTrp) cluster ing to 
another minor CLL subset. The third individual had no 
clonotype clustering to a stereotyped CLL subset.
Figure 2: Absolute monoclonal B-cell count, by phenotype 
CLL=chronic lymphocytic leukaemia. MBL=monoclonal B-cell lymphocytosis. 
Figure 3: LAIR1 expression pattern in monoclonal CD5-negative B cells 
MBL=monoclonal B-cell lymphocytosis.
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Genotype data generated for more than 5000 parti -
cipants of the Ugandan General Population Cohort are 
shown in the appendix (p 7).25 The prevalence of six SNPs 
that have been shown to be significantly associated both 
with CLL and with CLL-phenotype MBL were compared 
with published data from the UK14 on prevalence in the 
general population and in African Americans. For all of 
the SNPs associated with CLL-phenotype MBL, 
prevalence is substantially lower in rural Uganda than in 
the UK and in African Americans (appendix p 7). 
Discussion
In this cross-sectional study, we showed that the 
prevalence of MBL is marginally higher in rural Uganda 
than in the UK and that the phenotypes identified are 
different. By contrast, the incidence of B-lympho-
proliferative disorders is reported to be significantly 
lower in Africa than in Europe and the USA. However, 
detailed epidemiological studies are compromised by 
the fact that most patients with indolent 
B-lymphoproliferative disorders such as CLL and 
marginal zone lymphomas are asymptomatic and 
might be less likely to be diagnosed in African countries 
than in European or North American countries.2 
Therefore, more meaningful data could be obtained 
with population screening for the precursor disorders. 
MBL with a CLL phenotype is well charac terised, and 
results from a follow-up study16 have established that 
annually roughly 1% of individuals with CLL-phenotype 
MBL will develop symptomatic CLL that requires 
treatment. CLL-phenotype B cells are detectable at very 
low cell counts (often termed low-count MBL, typically 
<0·01 × 10⁹ cells per L) in 3–20% of adults in Europe 
and the USA, depending on assay sensitivity and age. 
Individuals with low-count MBL have a similar 
inherited susceptibility risk allele profile to those with 
CLL but no evidence of progression to clinical CLL.12–14,16 
CD5-negative MBL is less well characterised, mainly 
because of a lack of a lack of markers that differentiate 
neoplastic CD5-negative monoclonal B-cells from 
reactive monotypic expansions, but the available data 
suggest that it might be a precursor to marginal zone 
lymphoma, at least in some cases.20 However, the use of 
antigens such as LAIR1 and CXCR5 has improved the 
diagnosis of CD5-negative B-lymphoproliferative dis-
orders,22 potentially facilitating the detection of 
precursor lesions. 
Therefore, we used flow cytometry to assess, in detail, 
the prevalence of MBL in a rural Ugandan population 
who were HIV negative. We also compared this 
prevalence with that in an age-and-sex-matched UK 
control population, since such a comparison might 
provide insights into the relative incidences of both CLL 
and marginal zone lymphomas, independent of 
differences in health-care provision. Monoclonal B-cell 
populations were found with a similar frequency in 
adults from rural Uganda and the UK, but the type of 
monoclonal B-cell expansions seemed distinct. 
Subpopulations of CLL-phenotype monoclonal B-cells 
were detected frequently in the UK cohort but very rarely 
in Ugandan participants. By contrast, a much higher 
proportion of Ugandan participants had detectable 
CD5-negative monoclonal B cells in the peripheral blood 
than adults from the UK. 
In a preliminary immunophenotypic analysis, we 
identified some differences in expression of markers, 
including CD38, CD73, CD200, and CD307d. In 
individuals with a predominantly monoclonal B-cell popu-
lation, the expression pattern suggested neoplastic 
expansion; by contrast, in individuals with polyclonal 
B cells or light-chain restriction in a subset of B-cells, the 
pattern was suggestive of a reactive expansion. The data 
confirmed that phenotypically identified CD5-negative 
MBL is consistently associated with clonal B-cell receptor 
immunoglobulin expansion. We could not confirm the 
presence of CLL-phenotype monoclonal B cells at the 
molecular level. Moreover, the presence of non-CLL B-cell 
subpopulations with light-chain restriction does not 
necessarily correspond to mono clonal expansions and 
might reflect a reactive expansion. Further work to identify 
markers that discriminate between reactive and neoplastic 
expansions would greatly benefit the diagnostic process 
for post-germinal centre B-cell disorder. 
Further insights have been provided by immuno globulin 
gene repertoire analysis and SNP data.  Although the 
numbers of samples included in this study were small, our 
results suggest that CLL-specific IGHV–IGHD–IGHJ 
gene rearrangements might be detected in the rural 
Ugandan population without being associated with the 
detection of a CLL-phenotype MBL. This finding is notable 
because CLL-derived B-cell receptor immuno globulin 
molecules have a central role in CLL pathogenesis by 
transducing antigen-driven26 or antigen-independent cell-
autonomous signals, or both.27 Therefore, the presence of 
CLL-specific rearrangements without clonal expansion 
indicates that additional or alternative mechanisms are 
also necessary for the development and expansion of 
CLL-phenotype MBL. We also confirmed clonality in most 
CD5-negative MBL cases, although all cases had multiple 
expanded clonotypes, indicating that reactive expansions 
might also be common in rural Ugandans. Inherited 
susceptibility is an important factor in CLL: 30 common 
genetic variants have been identified so far and six have 
been confirmed in MBL.14,28 SNP analysis in the Ugandan 
cohort confirmed HapMap data showing that CLL 
susceptibility loci are very rare in this population. Although 
the absence of CLL susceptibility loci does not preclude 
development of CLL,29 some of the SNP are putatively 
causal for CLL.30 This finding, in combination with the 
MBL data, provides strong support for the hypothesis that 
inherited susceptibility affects the development of specific 
types of B-lymphoproliferative disorder.
In the UK, the prevalence of MBL subtypes closely 
reflects the incidence of clinical disease. CLL accounts 
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for a much higher proportion of B-lymphoproliferative 
disorders with detectable circulating disease than do 
other CD5-negative B-cell disorders.1 In this study, the 
prevalence of CD5-negative MBL in the UK cohort was 
similar to that reported in previous studies;5,6,18,19 however, 
the inclusion of LAIR1 in the screening process permitted 
detection of a larger proportion of cases with a 
monoclonal B-cell subset than has previously been 
reported. LAIR1 is negative or weakly expressed in most 
B-cell disorders, moderately expressed on most polyclonal 
B cells, and strongly expressed in hairy cell leukaemia.22 
Therefore, the use of LAIR1 expression greatly improves 
the sensitivity for detection of non-CLL-type monoclonal 
B-cell expansions, although whether these expansions 
represent a neoplastic precursor lesion or a reactive 
expansion remains to be determined.  The differences 
seen between the Ugandan cohort and UK cohort in 
regards to LAIR1 expression might reflect a further 
predisposition of the Ugandan population to the 
development of particular types of B-cell neoplasms, 
such as Waldenström’s macroglobulinaemia, which is 
predominantly LAIR1 negative or comprises both LAIR1-
positive and LAIR1-negative B-cell subpopulations, 
whereas hairy cell leukaemia typically shows strong 
LAIR1 expression.22 The use of a hospital-based study 
population has been shown to have a similar MBL 
prevalence to population-based studies using a similar 
screening sensitivity.5,6 However, the age and sex 
distribution of the UK study population in our study was 
selected to match the Ugandan cohort and might 
therefore under-represent population MBL prevalence. 
Therefore, further studies of MBL in the general UK 
population would be informative. 
Some data support the case that CD5-negative 
B-lymphoproliferative disorders are more common than 
CLL in Africa.3 The results of our study, with a higher 
prevalence of CD5-negative MBL than CLL-phenotype 
MBL, provide further evidence of geographical variation. 
This finding mirrors the results of Landgren and 
colleagues’ study,31 which showed that the prevalence and 
incidence patterns of myeloma are reflected in a much 
higher incidence of the precursor lesion monoclonal 
gammopathy of undetermined significance in Africans 
and African Americans than in Caucasians. Although the 
use of LAIR1 and CXCR5 expression helps to identify 
monoclonal or monotypic B-cell expansions, neoplastic 
populations are difficult to define accurately with only 
these markers because both markers show 
heterogeneous—and, for LAIR1, frequently bimodal—
expression in non-CLL B-lymphoproliferative disorders. 
Therefore, we propose that future studies should 
investigate the distribution of abnormal B-cell expansions 
by combining the sensitive approach of clonality with 
LAIR1 expression and a more specific phenotypic 
analysis—eg, the strong CD25 and weak CD22 expression 
seen in Waldenström’s macroglobulinaemia.32 This 
combined approach might help to improve understanding 
of the potential distribution of B-cell malignancies in the 
general African population. 
The use of an environmentally distinct population in 
rural Uganda in our study has some advantages for 
understanding the inherited susceptibility, but a 
limitation is that the rural Ugandan population might not 
be representative of the whole population in Uganda. In 
future studies, we aim to compare the rural and urban 
populations in Uganda, which would offer insights into 
the relative contribution of inherited susceptibility and 
environmental factors to the development of B-cell 
neoplasms. Although efforts were made to exclude people 
with immune suppression from this study, we cannot 
completely rule out the possibility that mild immune 
modulation was present in some participants. The small 
numbers of participants in our study relative to some 
studies in high-income countries might also affect 
results. 
To conclude, the prevalence of MBL is broadly similar 
in rural Uganda and the UK, but substantial qualitative 
differences exist, with a lower prevalence of CLL-
phenotype MBL and higher prevalence of CD5-negative 
MBL in the Ugandan cohort than in the UK cohort. 
These differences are likely to reflect variation in 
susceptibility alleles and antigenic exposure, which 
might affect the type of B-lymphoproliferative disorders 
that become clinically relevant. We believe that the study 
of MBL is an ideal platform to identify and study apparent 
differences in B-lymphoproliferative disorders in a way 
that is independent of health-care provision and referral 
biases, and to potentially allow validation of putative 
driver mutations using peripheral blood cells.33 
Additional data are required for confirmation of our 
findings, and more detailed biological data from patients 
with symptomatic disease, particularly splenic marginal 
zone lymphomas, are also needed. 
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